Cancer Deaths Declining by 1.5% a Year in the U.S.
Overall rates of cancer and cancer mortality in the United States continue to decline, according to the Annual Report to the Nation on the Status of Cancer.
CNS Cancers
Does Having a Respiratory Condition Lower the Risk of Glioma?
Patients with respiratory allergies, asthma, and eczema may be less likely to develop a glioma, according to a study published in the February issue of Cancer Epidemiology, Biomarkers & Prevention.
Possible New Tx for Pediatric Brain Tumors
An open-label, phase 2 trial showed acceptable toxicity and survival rates for the use of proton radiotherapy in children with medulloblastoma.
Novel Tx Granted Orphan Drug Status for Aggressive Brain Cancer
The FDA has granted Orphan Drug designation to marizomib (Triphase Accelerator) for the treatment of malignant glioma, an aggressive form of brain cancer with a significant unmet need due to its poor prognosis.
Optune Device Gains Expanded Indication
The U.S. Food and Drug Administration on Monday expanded its approval for the Optune device to include newly diagnosed glioblastoma multiforme.
Overweight, Obesity May Be Tied to Brain Tumor Risk
A new article published in Neurology suggests that being overweight or obese may be linked to an increased risk of developing meningioma, a type of brain tumor.
Chemoradiation for Glioblastoma Takes Toll on Brain
Structural changes include reduced gray matter volume and ventricular enlargement
Cracked Child-Resistant Bottle Caps Prompt Oncology Drug Recall
Merck announced a voluntary recall of Temodar (temozolomide) and its generic Temozolomide (Sandoz) capsules due to the potential for the bottle caps to be cracked.
Amneal Expands Generic Line With 4 New Products
Amneal announced the recent launch of four new products: Tobramycin Inhalation Solution, Memantine HCl Immediate Release Tablets, Temozolomide Capsules, and Divalproex Sodium Extended Release Tablets.
Toca 511 and Toca FC Fast Tracked for Recurrent High Grade Glioma
The Food and Drug Administration (FDA) has granted Fast Track status to Toca 511 and Toca FC for the treatment of recurrent high grade glioma, which includes glioblastoma and anaplastic astrocytoma.
